OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
Xiaoqing Yan, Ming Ye, Qing Zou, et al.
Annals of Oncology (2023) Vol. 35, Iss. 2, pp. 190-199
Open Access | Times Cited: 36
Xiaoqing Yan, Ming Ye, Qing Zou, et al.
Annals of Oncology (2023) Vol. 35, Iss. 2, pp. 190-199
Open Access | Times Cited: 36
Showing 1-25 of 36 citing articles:
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T. Powles, Laurence Albigès, Axel Bex, et al.
Annals of Oncology (2024) Vol. 35, Iss. 8, pp. 692-706
Closed Access | Times Cited: 68
T. Powles, Laurence Albigès, Axel Bex, et al.
Annals of Oncology (2024) Vol. 35, Iss. 8, pp. 692-706
Closed Access | Times Cited: 68
Renal cell carcinoma
Matthew R. Young, Francesca Jackson‐Spence, Luis Beltrán, et al.
The Lancet (2024) Vol. 404, Iss. 10451, pp. 476-491
Closed Access | Times Cited: 46
Matthew R. Young, Francesca Jackson‐Spence, Luis Beltrán, et al.
The Lancet (2024) Vol. 404, Iss. 10451, pp. 476-491
Closed Access | Times Cited: 46
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy
Domenico Izzo, Liliana Ascione, Lorenzo Guidi, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access | Times Cited: 3
Domenico Izzo, Liliana Ascione, Lorenzo Guidi, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access | Times Cited: 3
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
Toni K. Choueiri, Jaime R. Merchan, Robert A. Figlin, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 1, pp. 64-73
Closed Access | Times Cited: 3
Toni K. Choueiri, Jaime R. Merchan, Robert A. Figlin, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 1, pp. 64-73
Closed Access | Times Cited: 3
Novel small molecule inhibitors targeting renal cell carcinoma: Status, challenges, future directions
Lin Xiong, Ya Zhang, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116158-116158
Open Access | Times Cited: 13
Lin Xiong, Ya Zhang, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116158-116158
Open Access | Times Cited: 13
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
Regina Barragán-Carrillo, Eddy Saad, Renee-Maria Saliby, et al.
European Urology (2024)
Closed Access | Times Cited: 12
Regina Barragán-Carrillo, Eddy Saad, Renee-Maria Saliby, et al.
European Urology (2024)
Closed Access | Times Cited: 12
Case report: Tongue metastasis as an initial sign of clear cell renal cell carcinoma and its prognosis
Shuo Liu, Hongyun Liu, Bowen Weng, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access | Times Cited: 1
Shuo Liu, Hongyun Liu, Bowen Weng, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access | Times Cited: 1
Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial
Jiwei Huang, Yueming Wang, Fan Xu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e008475-e008475
Open Access | Times Cited: 4
Jiwei Huang, Yueming Wang, Fan Xu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e008475-e008475
Open Access | Times Cited: 4
Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma
Gengrun Wu, Teng Li, Yuanbiao Chen, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Gengrun Wu, Teng Li, Yuanbiao Chen, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Multifunctional Nanotherapeutics with Long-Acting Release against Macular Degeneration by Minimally Invasive Administration
Wanwan Chang, Xinying Lv, Jiafei Zhu, et al.
ACS Nano (2024)
Closed Access | Times Cited: 4
Wanwan Chang, Xinying Lv, Jiafei Zhu, et al.
ACS Nano (2024)
Closed Access | Times Cited: 4
2023 European Society for Medical Oncology (ESMO) Congress
Kim N., Christina Canil, Nimira Alimohamed, et al.
Canadian Urological Association Journal (2023) Vol. 18, Iss. 1, pp. E46-52
Open Access | Times Cited: 11
Kim N., Christina Canil, Nimira Alimohamed, et al.
Canadian Urological Association Journal (2023) Vol. 18, Iss. 1, pp. E46-52
Open Access | Times Cited: 11
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
Hua Xu, Xin Yao, Zhisong He, et al.
Targeted Oncology (2025)
Closed Access
Hua Xu, Xin Yao, Zhisong He, et al.
Targeted Oncology (2025)
Closed Access
Research progress on intratumoral microorganisms in renal cancer
Jiankun Zhang, Keyuan Lou, Junpeng Chi, et al.
World Journal of Urology (2025) Vol. 43, Iss. 1
Closed Access
Jiankun Zhang, Keyuan Lou, Junpeng Chi, et al.
World Journal of Urology (2025) Vol. 43, Iss. 1
Closed Access
Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study
Zhongjie Zhao, Zhengsheng Liu, Kaiyan Zhang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Zhongjie Zhao, Zhengsheng Liu, Kaiyan Zhang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Optimization of Immunotherapy-Based Combinations for Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
Sohyeon Park, K. W. Park, Misung Kim, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104630-104630
Closed Access
Sohyeon Park, K. W. Park, Misung Kim, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104630-104630
Closed Access
Sorafenib-induced cardiovascular toxicity: a cause for concern
Zheng Deng, Shuang Xiao, Yingying He, et al.
Chemico-Biological Interactions (2025), pp. 111388-111388
Closed Access
Zheng Deng, Shuang Xiao, Yingying He, et al.
Chemico-Biological Interactions (2025), pp. 111388-111388
Closed Access
Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish ‘Cambados annual meeting’
I. Peláez, Martín Lázaro, Daniel Pérez-Fentes, et al.
Clinical & Translational Oncology (2025)
Closed Access
I. Peláez, Martín Lázaro, Daniel Pérez-Fentes, et al.
Clinical & Translational Oncology (2025)
Closed Access
GAMT facilitates tumor progression via inhibiting p53 in clear cell renal cell carcinoma
Bin Zheng, Kan Liu, J. Feng, et al.
Biology Direct (2025) Vol. 20, Iss. 1
Open Access
Bin Zheng, Kan Liu, J. Feng, et al.
Biology Direct (2025) Vol. 20, Iss. 1
Open Access
Biology of renal cancer tumor thrombus - towards the personalized approach
Sumit Sharma, Michał Kunc, Mieszko Czapliński, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104731-104731
Closed Access
Sumit Sharma, Michał Kunc, Mieszko Czapliński, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104731-104731
Closed Access
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 7
Open Access
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 7
Open Access
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma
Alessandro Samuelly, Rosario Francesco Di Stefano, Fabio Turco, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 307-307
Open Access | Times Cited: 3
Alessandro Samuelly, Rosario Francesco Di Stefano, Fabio Turco, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 307-307
Open Access | Times Cited: 3
Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma
Siwei Yang, Xianrui Yang, Zekai Hou, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e29215-e29215
Open Access | Times Cited: 1
Siwei Yang, Xianrui Yang, Zekai Hou, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e29215-e29215
Open Access | Times Cited: 1
Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study
Liangyou Gu, Cheng Peng, Qiyang Liang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Liangyou Gu, Cheng Peng, Qiyang Liang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF‐2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma
Yihao Zhu, Yajian Li, Xu‐Wen Li, et al.
Advanced Healthcare Materials (2024)
Open Access | Times Cited: 1
Yihao Zhu, Yajian Li, Xu‐Wen Li, et al.
Advanced Healthcare Materials (2024)
Open Access | Times Cited: 1
Application of extended immunotherapy in advanced clear cell renal cell carcinoma treated with first-line combination of immune-checkpoint inhibitor and tyrosine kinase inhibitor
Qian Wang, Xingming Zhang, Qiyu Zhu, et al.
International Urology and Nephrology (2024)
Closed Access | Times Cited: 1
Qian Wang, Xingming Zhang, Qiyu Zhu, et al.
International Urology and Nephrology (2024)
Closed Access | Times Cited: 1
